<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Q418/FY18 Advanced Wound Care Market Recap

Posted by Susan Paquette on 4/18/19 9:30 AM

Dressings recover Q418, all segments showing solid gains

For FY18, according to BioMedGPS’  SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics were up +4.1% YoY.  Acelity remains the global market leader followed by S&N and Mölnlycke. Advanced Dressings, the workhorse of Advanced Wound Care, accounts for 52.3% of WW revenues, up +3.3% YoY. Skin/Dermal Substitute (CTP) revenue was up +10.7% YoY, lower than previous years, but still double-digit gains. WW NPWT was up +4.3% YoY, with traditional devices having a slight uptick and single-use driving the increase of +28.9%.

Among the many topics covered in the Q418/FY18 Advanced Wound Care Market Recap are:

Read More

Topics: Advanced Wound Care, Q418 Market Recaps

S&N Solidifies its Leadership Position in Wound Biologics

Posted by Susan Paquette on 4/15/19 12:00 PM

S&N plans to shore up its Advanced Wound Bioactives business with the acquisition of Osiris Therapeutics but the deal may be in question as Osiris shareholders challenge the price.

 Smith & Nephew (S&N) announced on March 12, 2019 that it has agreed to acquire Osiris Therapeutics for $660MM with the deal expected to close Q219. However, the deal could be in question as a group of Osiris shareholders is suing to block the acquisition. The lawsuit disputes Cantor Fitzgerald’s discounted cash flow analysis, saying it does not adequately reflect Osiris’s future growth prospects, and is based on growth rates that are about half of what Osiris has experienced in recent years, resulting in a valuation that is too low. The acquisition would add the Osiris’s Grafix and Stravix product lines to S&N’s ailing Advanced Wound Bioactives portfolio. If allowed to proceed, the acquisition would solidify S&N’s leadership in wound biologics and changes the competitive landscape in the Advanced Wound Care market...

Read More

Topics: Advanced Wound Care

Q418/FY18 Market Recap: US Hemostats and Sealants

Posted by Doug Devens on 4/9/19 1:39 PM

The US market for Hemostats and Sealants accelerated in Q418 driven by growth in fibrin sealants and thrombin hemostats, overcoming slow growth during the first half of the year.

The US market for Hemostats and Sealants accelerated with +9.3% YoY growth in Q418, continuing to build on its +7.9% YoY in Q318, with fibrin sealants and thrombin hemostats driving the increase. The US market grew +6.1% in FY18, overcoming slow growth during the first half of the year.

As reported in SmartTRAK Financial Dashboard, every manufacturer in the Hemostats and Sealants market, except Pfizer and CryoLife, experienced revenue growth in Q418. Leading the way was Baxter with +33.1% YoY growth as it made progress with its integration of the Mallinckrodt portfolio. Ethicon and Becton Dickinson (BD) both posted solid gains, with +8.7% YoY and +6.6% YoY growth, respectively...

Read More

Topics: Biosurgery-Hemostats and Sealants, Q418 Market Recaps

Q418/FY18 Market Recap: SCS Market Slows

Posted by Anne Staylor on 4/9/19 10:12 AM

The Spinal Cord Stimulation (SCS) market saw high-teens growth in FY18, but decelerated in Q418.

The US SCS Market saw another banner year in FY18, growing +17.4% YoY. Market growth was driven by new product launches, expanding indications and ongoing demand for non-narcotic alternatives that address chronic intractable pain and the opioid epidemic.

Read More

Topics: Neuromodulation-Spinal Cord Stimulation

SmartTRAK's Q418/FY18 OrthoBio Market Recap

Posted by Kim French on 4/8/19 2:00 PM

Advanced, higher priced biologics push the US OrthoBio Market higher

Based on Q418/FY18  SmartTRAK Financial Dashboard reporting:
  • US Bone Replacement grew +2.3% YoY, with FY18 revenues up +2.7%.
  • US Cartilage Replacement increased 55.7% YoY, with FY18 revenues up 34.7%.
  • US Soft Tissue Augmentation grew 2.3%, with FY18 revenues growing 9.2%.
  • US Tendon Allografts posted an 8.4% YoY increase, with FY18 revenues up +3.9% YoY
  • US Meniscal Implant market, with robust growth, was up 15.6% YoY for Q418 with FY18 revenues increasing by 3.0%.

Among the many topics covered in the Q418/FY18 OrthoBio Market Recap are:

Read More

Topics: OrthoBio, Q418 Market Recaps

SmartTRAK Cited in Smith & Nephew Osiris Acquisition Press Release

Posted by Susan Paquette on 4/8/19 10:13 AM

SmartTRAK was cited as a source in a press release from Smith & Nephew entitled "Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc."

Read More

Topics: Advanced Wound Care

Q418/FY18 Market Recap: US Surgical Matrices

Posted by Doug Devens on 4/5/19 9:45 AM

The US Surgical Matrices Market continued to advance in Q418, driven by a resurgence of Becton Dickinson in hernia matrices and continued growth of breast matrices.  The US market grew +9.7% in FY18.

SmartTRAK reports that the US Surgical Matrices market grew in both the Breast and Hernia Repair segments. SmartTRAK estimates the Breast segment grew again at +21.8% YoY growth to 35.2% share of the entire Surgical Matrices market. The Hernia Repair market continued its recovery up +4.8% YoY and 64.8% share of the US Surgical Matrices Market in Q418.  

Among the many topics covered in the Q418/FY18 Surgical Matrices Market Recap are:

Read More

Topics: Advanced Wound Care-Surgical Matrices, Q418 Market Recaps

Q418/FY18 Infection Prevention: Vascular Access Adjunct Products

Posted by Susan Paquette on 4/3/19 11:25 AM

FY18 showed solid gains in all segments, up +5.7% YoY, as antimicrobial devices take the lead.

Prevention of HAIs continues to drive measures and practices to reduce Central Line Associated Bloodstream Infections (CLABSIs) and create demand for products that can aid in addressing these issues. Progress is being made and updated new patient safety data continues to show a downward trend in the annual number of hospital-acquired conditions. According to new analysis from AJRQ, hospital-acquired conditions (HACs) dropped 13% from 2014 to 2017. However, the number of SSIs did not change over the 3 years while CLABSI’s reported an estimated -6% decline from 2014 to 2017 (preliminary data).
Read More

Topics: Wound Care-Infection Prevention, Q418 Market Recaps

SmartTRAK's Q418/FY18 Spine Market Recap

Posted by Julianne Burns on 4/1/19 12:28 PM

Q418 US Spine market remains fairly flat, rounding out a stable but unremarkable FY18.

SmartTRAK’s Financial Dashboard indicates a fairly flat Q418 US Spine market, with a decline of -0.4%. Similarly, for the full year, the US Spine Market was stable, with +0.9% growth. WW revenues increased modestly with a +1% uptick for FY2018. Spine market growth as a whole slowed sequentially to +1% in Q418 from +2% in Q3 according to estimates. Growth continues to be restricted in the US Spine market by a few key factors. Payer pushback is the norm, and while most surgical practices have learned to deal with it, the environment is ever-changing with new obstacles and hurdles.

Among the many topics covered in SmartTRAK's Q418/FY18 Spine Market Recap are:

Read More

Topics: Orthopedics-Spine, Q418 Market Recaps

Customize Your SmartTRAK Updates Email!

Posted by Rebecca Gonzalez on 3/31/19 6:55 PM

SmartTRAK Subscribers: See only news for the Markets, Modules and Segments that you care about!

Have you ever wished that you could customize your SmartTRAK Daily Updates Email so that you can see ONLY news about the SmartTRAK Markets, Modules and Segments that you care about? And save yourself time from scrolling through all the Markets, Modules and Segments that your company subscribes to? 

Read More

Topics: Your SmartTRAK News

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts